Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide and Sintilimab in Advanced High-grade Neuroendocrine Neoplasm
NCT05113355Phase 2Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Nov 2021
- Primary completion
- Nov 2022
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat and sintilimab in Neuroendocrine neoplasm (NEN), sponsored by Peking Union Medical College Hospital. Primary endpoint: Objective Response Rate at 2 years. Status: unknown.
02
Drugs
tucidinostatsintilimab
03
Conditions
Neuroendocrine neoplasm (NEN)
Beyond the preview
Go deeper on NCT05113355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05113355.